Cachexia is a disorder involving dangerous weight loss brought on by diseases as diverse as AIDS, cancer or Alzheimer’s. A 2011 German study involving more than 100 people proved that patients on the placebo lost about 80 percent more weight weekly than those administered a cannabinoid cocktail. This, along with the mood-elevating properties of cannabidiol implies future applications for the treatment of widespread eating disorders such as anorexia nervosa.
CBD derived from marijuana is a different story, and the law varies from state to state. But as long as you’re using CBD oil that contains less than 0.3 percent THC, you have nothing to be concerned about anywhere in the United States. On the other hand, if you want to take your CBD on a trip outside the country, definitely look into local laws to avoid getting into awkward situations while you’re away.

‘I recommend starting with a low dose and slowly building up over a few weeks, to find the dose that works best for you,’ agrees Dr Brewer. ‘For example, start with Healthspan High Strength CBD Oil 6.4mg Capsules, taking one to three daily. Then, if needed, move up to Super Strength CBD 15mg Capsules, taking one to two daily. CBD is not psychoactive and is not addictive. I prefer capsules, as CBD drops have a strong taste, although filter-clear peppermint flavoured drops are available.’ 

Hemp oil (also called hemp seed oil) is extracted from the hemp seeds of the hemp plant and it contains very little or no THC. Cannabis, on the other hand, has THC levels above 0.3 percent (usually between 5-35 percent). Because of its low THC levels, you can use hemp oil without feeling “high” afterwards. Hemp is typically grown for industrial purposes, as it’s used to make clothing, paper, ropes, carpets, construction materials and plastic composites.
The heat is very much on CBD oil sellers these days as the FDA continues to crack down on companies selling “questionable” (to put it nicely) hemp-based products. In fact, since 2015 – when the FDA first issued warning letters to multiple CBD sellers – the industry has been forced to clean up its act, at least in terms of manufacturing operations and brand transparency.

As one might expect from the information presented in the previous sections of this article, the position of cannabidiol (both from a medical and from an institutional point of view) is one of uncertainty. To add insult to injury, private companies (especially those targeting immediate profit with a minimum of investment) take advantage of the loopholes in legislation to gain from the media exposure that CBD has had in the past few years.
A survey of patients seen in a tertiary epilepsy center found that 21% of patients admitted to using marijuana in the last year, and 24% of patients believed marijuana to be effective for their seizures (10). While interesting, this anecdotal observation does not rise to the level of evidence needed to evaluate a potential new therapeutic modality.
×